Incyte Forecast, price target & analysts
Incyte Target price 2026 - Analyst rating & recommendation
Incyte Classifications & Recommendation
Incyte Price Target
| Target Price | $132.60 |
| Price | $115.30 |
| Potential |
15.00%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Incyte 2027 .
The average Incyte target price is $132.60.
This is
15.00%
register free of charge
$162.75
41.15%
register free of charge
$88.60
23.16%
register free of charge
|
|
| A rating was issued by 35 analysts: 18 Analysts recommend Incyte to buy, 17 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Incyte stock has an average upside potential 2027 of
15.00%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 5.14 | 6.06 |
| 21.22% | 17.83% | |
| EBITDA Margin | 26.62% | 16.03% |
| 734.67% | 39.77% | |
| Net Margin | 25.03% | 11.76% |
| 3,153.86% | 53.01% |
30 Analysts have issued a sales forecast Incyte 2026 . The average Incyte sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Incyte EBITDA forecast 2026. The average Incyte EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
30 Incyte Analysts have issued a net profit forecast 2026. The average Incyte net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 6.41 | 3.55 |
| 4,173.33% | 44.62% | |
| P/E | 32.52 | |
| EV/Sales | 3.11 |
30 Analysts have issued a Incyte forecast for earnings per share. The average Incyte EPS is
This results in the following potential growth metrics and future valuations:
Current Incyte Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 01 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 28 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 01 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 28 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 17 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
